Atezolizumab( —— )

Catalog No. M22134 CAS No. 1380723-44-3

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Atezolizumab
Note

Research use only, not for human use.
Brief Description

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
Description

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.
In Vitro

Atezolizumab (0, 2.5, 5, 10, 20, and 40?μg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells.Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway. Atezolizumab (10?μg/ml; 24?hours; HOS and 143B cells) induces autophagy in osteosarcoma cells.
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Other Targets
Research Area

——
Indication

——

1. Inman BA, et al. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1886-1890.

Calculator

molnova catalog